Acumen Pharmaceuticals (ABOS) to Release Earnings on Thursday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.47) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Acumen Pharmaceuticals Price Performance

Shares of NASDAQ:ABOS opened at $1.24 on Tuesday. The firm’s 50 day moving average price is $1.41 and its 200-day moving average price is $2.02. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $74.50 million, a PE ratio of -0.90 and a beta of 0.02. Acumen Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $4.39.

Insider Transactions at Acumen Pharmaceuticals

In related news, CEO Daniel Joseph Oconnell sold 47,778 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the completion of the sale, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at approximately $836,660.88. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Matt Zuga sold 28,902 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the completion of the sale, the chief financial officer now directly owns 231,744 shares of the company’s stock, valued at approximately $398,599.68. This trade represents a 11.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 131,526 shares of company stock worth $233,124 in the last 90 days. 7.10% of the stock is currently owned by insiders.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.